6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03970798 (ClinicalTrials.gov)	May 22, 2019	23/5/2019	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	Parkinson's Disease	Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	50	Phase 1	Japan
2	JPRN-UMIN000022187	2016/05/06	06/05/2016	Research on Parkinson's disease pathogenesis based on analysis of caffeineabsorption in patients wit ...	Research on Parkinson's disease pathogenesis based on analysis of caffeineabsorption in patients wit ...	Parkinson's disease	PD group, 200 mg caffeineadministration, qd, 1 day Control group, 200 mg caffeineadministration, qd, ...	Department of Neurology, Juntendo University	NULL	Complete: follow-up complete	40years-old	60years-old	Male and Female	20	Not applicable	Japan
3	NCT01738178 (ClinicalTrials.gov)	April 2014	28/11/2012	Caffeine as a Therapy for Parkinson's Disease	Caffeine as a Therapeutic Agent in Parkinson's Disease	Parkinson's Disease	Drug: Caffeine;Drug: Placebo	McGill University Health Center	Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and East ...	Completed	45 Years	75 Years	All	119	Phase 3	Brazil;Canada
4	NCT01190735 (ClinicalTrials.gov)	August 2010	26/8/2010	Caffeine for Motor Manifestations of Parkinson's Disease	Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.	Parkinson's Disease	Drug: Caffeine alkaloid	Ron Postuma	Canadian Institutes of Health Research (CIHR)	Completed	18 Years	N/A	Both	28	Phase 2	Canada
5	NCT00459420 (ClinicalTrials.gov)	April 2007	11/4/2007	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Parkinson's Disease;Excessive Daytime Somnolence	Drug: Caffeine 100-200 mg BID;Drug: placebo	Ron Postuma	Canadian Institutes of Health Research (CIHR);University of Toronto	Completed	18 Years	N/A	Both	58	Phase 2/Phase 3	Canada

First Previous1Next Last